INVESTOR RELATIONS
INVESTOR RELATIONS

COMMUNICATION WITH SHAREHOLDERS

 

Pursuant to Article 5(5) of the Law of 15 September 2000 Commercial Companies Code (Journal of Laws of 2000, No. 94, item 1037, as further amended) in the wording in force from 1 January 2020, on the basis of the amendment made by the Act of 30 August 2019 amending the Commercial Companies Code and certain other acts (Journal of Laws of 2019, item 1798), a joint stock company is obliged to maintain its own website and also to place on this website, in places designated for communication with shareholders, the announcements required by law or by the statute from the company.

 

 

INFORMATION ABOUT THE CALL FOR SUBMISSION OF THE DOCUMENTS OF SHARES

 

                    The Management Board of HELIX IMMUNO-ONCOLOGY S.A. with its seat in Gliwice at Bojkowska 59C, 44-100 Gliwice,

                    entered into the Register of Entrepreneurs of the National Court Register under KRS number: 0000692806, District

                    Court in Gliwice, 10th Commercial Department of the National Court Register, with the share capital of PLN

                    1,321,950.00 paid in full, NIP: 5252547574, REGON: 146535883 (hereinafter also referred to as the "Company"), in

                    performance of the obligation arising from Article 16 section 1 of the Act of 30 August 2019 amending the Act

                    Commercial Companies Code and certain other acts (Journal of Laws of 2019, item 1798 as amended - hereinafter

                    also referred to as the "Act") hereby calls the shareholders of HELIX IMMUNO-ONCOLOGY S.A. to submit to the

                    Company, by 31 January 2021, the documents of shares (collective share certificates).

 

                    The documents of shares may be submitted to the Company's office in Warsaw at the address: Gen. Sylwestra

                    Kaliskiego 2B, 00-908 Warsaw, from Monday to Friday from 9:00 am to 15:00 pm. The documents of shares shall be

                    submitted to the Company upon a written receipt issued to the shareholder.

 

                    At the same time the Company informs that:

 

 

                          1. the call for submission of the documents of shares is connected with the mandatory dematerialization of

                              shares introduced by the Act;

                          2. the call for submission of the documents of shares is addressed to the shareholders five times at an interval of

                              not more than one month and not less than two weeks;

                          3. the Company makes information about the call available on the Company's website in a place designated for

                              communication with shareholders for a period not shorter than three years from the date of the first call;

                          4. the documents of shares issued by the Company expire by virtue of law on 1 March 2021; on the same day,

                              the entries in the register of shareholders kept by the entity elected by a resolution of the General Meeting of

                              the Company become legally binding;

                          5. the documents of shares shall remain valid only to the extent that the shareholder demonstrates to the

                              Company that the shareholder is entitled to share rights for a period of five years from the effective date of

                              the Act;

                          6. the Company has made an individual call for shareholders to submit the documents of shares to the Company

                              in a manner appropriate for convening the Company's General Meeting.

 

 

                    The Company's Management Board:

                    Ireneusz Fąfara - President of the Management Board

                    Paweł Wiśniewski - Vice-President of the Management Board

 

 

                    On 3 September 2020, the Extraordinary General Meeting of Helix Immuno-Oncology S.A. (hereinafter referred to as

                    the "Company") adopted a resolution on the matter:

 

                          1. Increase of the Company's share capital by the amount of PLN 558,518.50 by issuing 5 585 185 ordinary

                              registered shares with a nominal value of PLN 0.10 marked as series C, depriving the existing shareholders of

                              the right to subscribe for shares in full and amending the Company's Articles of Association;

                          2. Adoption of the consolidated text of the Company's Articles of Association.

 

                    As a consequence of the adoption by the Extraordinary General Meeting of the Company of the above resolutions,

                    5 585 185 ordinary registered shares with a nominal value of 0.10 PLN marked as series C were taken up by the

                    company named ACRX INVESTMENTS LIMITED with its registered seat in Nicosia (Cyprus), by way of private

                    subscription. Series C shares were taken up in exchange for cash contribution. The issue price of series C shares is

                    PLN 1.35.

 

 

      REGISTRATION OF THE COMPANY'S SHARE CAPITAL INCREASE

 

                    On 8 July 2020, the registry court - District Court in Gliwice, 10th Commercial Division of the National Court Register,

                    registered the increase in the share capital of Helix Immuno-Oncology S.A. The fully paid-up share capital of the

                    Company is currently PLN 1,321,950.00.           

 

 

      INCREASE OF THE COMPANY'S SHARE CAPITAL

 

                     On 23 June 2020, the Extraordinary General Meeting of Helix Immuno-Oncology S.A. (hereinafter referred to as the

                     "Company") adopted a resolution on the matter:

 

                           1. Increase of the Company's share capital by the amount of PLN 220,000 (two hundred and twenty thousand

                               zlotys) by issuing 2,200,000 (two million two hundred thousand) ordinary registered shares with a nominal

                               value of PLN 0.10 (ten groszy) marked as series B, depriving the existing shareholders of the right to

                               subscribe for shares in full and amending the Company's Articles of Association.

 

                           2. Adoption of the consolidated text of the Company's Articles of Association.

 

                     As a consequence of the adoption by the Extraordinary General Meeting of the Company of the above resolutions,

                     2,200,000 (two million two hundred thousand) ordinary registered shares with a nominal value of 0.10 PLN (ten

                     groszy) marked as series B were taken up by JR Holding Alternatywna Spółka Inwestycyjna S.A. with its seat in

                     Krakow, by way of private subscription. Series B shares were taken up in exchange for cash contribution. The issue

                     price of series B shares is PLN 1.35 (one zloty thirty-five groszy) per share, i.e. the total cash contribution of the

                     investor amounted to PLN 2,970,000 (two million nine hundred seventy thousand zloty). The share subscription

                     agreement was concluded on 24 June 2020. The shares taken up by the investor constitute a 16.64 % share in the

                     increased share capital of the Company, giving 2,200,000 (two million two hundred thousand) votes, which after the

                     registration of the share capital increase by the registration court, constitute a 16.64 % share in the total number of

                     votes.

 

 

      CHANGES IN THE MANAGEMENT BOARD OF HELIX IMMUNO-ONCOLOGY S.A.

 

                     On 4 June 2020, the Extraordinary General Meeting of HELIX IMMUNO-ONCOLOGY S.A.adopted resolutions on the

                     changes in the Company's Management Board, entrusting the role of the President of the Management Board as of 5

                     June 2020 to Mr. Ireneusz Fąfara and the role of the Vice-President of the Management Board to Mr. Paweł Wiśniewski.

 

                     Since 5 June 2020, the Company's Management Board has been composed of two members, as follows:

                           1.Ireneusz Fąfara - President of the Management Board

                           2. Paweł Wiśniewski - Vice-President of the Management Board

 

 

 

      SUBMITTING DOCUMENTS TO THE FINANCIAL DOCUMENTS REPOSITORY

                      

                       On 5 February 2020, HELIX IMMUNO-ONCOLOGY S.A. submitted the following documents for the financial year from

                       1 August 2018 to 31 July 2019 to the Financial Documents Repository:

               

                           1. the financial statements,

                           2. the Management Board’s report on company activity,

                           3. the auditor's opinion / audit report on the annual financial statements,

                           4. the resolution on profit distribution or loss coverage,

                           5. the resolution to approve the financial statements.

 

 

ABOUT THE COMPANY

 

      COMPANY

 

                        HELIX IMMUNO-ONCOLOGY S.A. is a subsidiary of Helix BioPharma Corp. The shares of Helix BioPharma Corp. are

                        currently listed on the Toronto Stock Exchange (TSX) under the symbol "HBP". HELIX IMMUNO-ONCOLOGY S.A.

                        completed the process of transformation from a limited liability company into a joint stock company in 2017. This is

                        the first step on the way to the company's debut on the Warsaw Stock Exchange.

 

                        HELIX IMMUNO-ONCOLOGY S.A. actively works on developing innovative products used in cancer therapy. The

                        company's activities in developing potential drugs are based on a technological platform: Tumour Defence Breaker

                        (DOS47), and in particular works on the development of the V-DOS47 molecule, which is used to treat breast

                        cancer and other solid cancers.

 

                        HELIX IMMUNO-ONCOLOGY S.A.

                        Bojkowska 59C Street

                        44-100 Gliwice

                        NIP: 5252547574

                        REGON: 146535883

               share capital: 1.321.950,00 PLN

               entirely paid

               KRS: 0000692806

               District Court in Gliwice

               10th Economic Department of the National Court Register

 

 

      COMPANY AUTHORITIES

 

         

         THE MANAGEMENT BOARD

 

                        Ireneusz Fąfara – President of the Management Board

                        Dr Paweł Wiśniewski - Vice-President of the Management Board

 

 

         SUPERVISORY BOARD

 

                        Prof. Sławomir Majewski - Chairman of the Supervisory Board

                        Dr Heman Chao - Member of the Supervisory Board

                        Andreas Kandziora - Member of the Supervisory Board

 

 

         CONTACT

 

                        Contact for investors:

 

                        Paweł Wiśniewski – Vice-President of the Management Board

                        e-mail: pawel.wisniewski@helixpolska.com

 

                        Please read our Privacy Policy